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ABSTRACT
Among rare diseases caused bymutations in LMNA gene, Emery-Dreifuss Muscular Dystrophy type 2 and
Limb-Girdle muscular Dystrophy 1B are characterized by muscle weakness and wasting, joint
contractures, cardiomyopathy with conduction system disorders. Circulating biomarkers for these
pathologies have not been identiﬁed. Here, we analyzed the secretome of a cohort of patients affected
by these muscular laminopathies in the attempt to identify a common signature. Multiplex cytokine
assay showed that transforming growth factor beta 2 (TGF b2) and interleukin 17 serum levels are
consistently elevated in the vast majority of examined patients, while interleukin 6 and basic ﬁbroblast
growth factor are altered in subgroups of patients. Levels of TGF b2 are also increased in ﬁbroblast and
myoblast cultures established from patient biopsies as well as in serum from mice bearing the H222P
Lmna mutation causing Emery-Dreifuss Muscular Dystrophy in humans. Both patient serum and
ﬁbroblast conditioned media activated a TGF b2-dependent ﬁbrogenic program in normal human
myoblasts and tenocytes and inhibited myoblast differentiation. Consistent with these results, a TGF b2
neutralizing antibody avoided ﬁbrogenic marker activation and myogenesis impairment. Cell intrinsic
TGF b2-dependent mechanisms were also determined in laminopathic cells, where TGF b2 activated
AKT/mTOR phosphorylation. These data show that TGF b2 contributes to the pathogenesis of Emery-
Dreifuss Muscular Dystrophy type 2 and Limb-Girdle muscular Dystrophy 1B and can be considered a
potential biomarker of those diseases. Further, the evidence of TGF b2 pathogenetic effects in tenocytes
provides the ﬁrst mechanistic insight into occurrence of joint contractures in muscular laminopathies.
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Introduction
Emery-Dreifuss Muscular Dystrophy (EDMD) is a rare
genetic condition causing elbow and Achilles tendon
contractures, rigid spine, muscle weakness and wasting
and cardiomyopathy with conduction system disorder
[1]. Signs of lipodystrophy are observed in a signiﬁcant
percentage of EDMD patients [2,3]. The disease is
linked to mutations in nuclear envelope/lamina genes
including LMNA, EMD, SYNE 1/2 and can be also
caused by FHL1 mutations or worsened by modiﬁers
such as SUN1 and SUN2, also encoding nuclear enve-
lope proteins [4]. We have previously described patho-
genetic mechanisms of EDMD by showing that LMNA
mutations affect lamin A/C levels and phosphorylation
[5] and cause clustering of myonuclei, an effect also
involving SUN1 and SUN2 [6]. Although muscle
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SPECIAL ISSUE ON LAMINOPATHIES
weakness and wasting can be in part explained by those
mechanisms as well as by altered expression of myo-
genic genes downstream of altered lamin-dependent
chromatin regulation [4,7], those ﬁndings can barely
account for some off-target effects such as neck adipose
tissue hypertrophy, ankle and elbow contractures or for
variable severity of disease among patients [1]. In recent
studies [8,9], off-target effects in muscular dystrophy
have been ascribed to systemic factors. In Duchenne
muscular dystrophy mouse models and human tissues,
altered transforming growth factor beta 2 (TGF b2)
secretion has been reported and linked to either bone
defects or muscle ﬁbrosis or both [8, 9]. Moreover,
TGF b2-dependent ﬁbrogenic conversion of muscle
cell precursors has been demonstrated in the mouse
model of Duchenne muscular distrophy (Mdx mice)
[9]. Along this line, inhibition of TGF b release by
latent TGF b-binding protein ameliorated the dystro-
phic phenotype in the same mouse model [10]. Altered
TGF b signaling has been also reported in laminopa-
thies. In Mandibuloacral Dysplasia, a mild progeroid
laminopathy with skeletal and adipose tissue involve-
ment, increase of TGF b2 secretion in cells and serum
has been reported and the effect has been linked to acti-
vation of the AKT/mTOR pathway leading to produc-
tion of pro-osteoclastogenic factors and bone
resorption activity [11, 12]. Moreover, enhanced AKT
and mTOR phosphorylation was observed in
LmnaH222P/H222P P mice at 4 weeks of age and phos-
phorylation further increased with age [13-16]. This
effect was associated with autophagy impairment and
was rescued by temsirolimus and selumetinib, drugs
that activate the autophagic pathway [14]. Of note, in
this mouse model, upregulation of TGFbeta 2 mRNA
and activation of downstream signaling has been
recently demonstrated [13].
In a comprehensive analysis, we have described and
critically reviewed the phenotype of a cohort of Italian
patients affected by type 2 EDMD (EDMD2), the
muscular dystrophy caused by LMNA mutations [1].
In the study here reported, samples from those indi-
viduals were collected, other samples from lamino-
pathic patients affected by Limb-Girdle muscular
Dystrophy 1B (LGMD 1B) were also included and lev-
els of cytokines, chemokines and growth factors were
determined in serum and cell culture medium. This
paper reports the results of the analysis and shows
that TGF b2 is consistently elevated in the vast major-
ity of EDMD2 patients, irrespective of gender and age.
Moreover, TGF b2 levels are higher in EDMD2 than
in other muscular dystrophies. At the cellular level,
TGF b2 increase impairs myogenic differentiation and
elicits expression of pro-ﬁbrotic genes both in myo-
blasts and tenocytes. Moreover, tenocytes cultured in
the presence of EDMD2 patient serum show upregula-
tion of tenomodulin, a TGF b2-induced differentiation
marker. Our data suggest a TGF b2 neutralizing anti-
body as a potential pharmacological tool to be
explored in animal models and identify circulating
TGF b2 as biomarker for EDMD2 and LGMD 1B.
Results
TGF b2 increase in EDMD2 serum
The multiple cytokine analysis of EDMD2 and LGMD
1B sera showed that TGF b2 was elevated in the vast
majority of affected patients irrespective of gender and
age (Fig. 1A). TGF b2 increase was much more signiﬁ-
cant in EDMD2 than in other neuromuscular diseases
including Duchenne Muscular dystrophy (DMD),
Becker muscular dystrophy (BMD) and Myotonic
Dystrophy (MD) (Fig. 1A). Other cytokines affected
in EDMD2 sera were Interleukin (IL) 17 (IL17) that
was increased to a variable extent in most patients and
basic FGF (FGF-b), although this growth factor was
increased in subgroups of patients (LMNA1 and 3,
Fig. 1B) and decreased in other patients (LMNA2
group, Fig. 1B). IL6 was increased in two subgroups of
patients, the ﬁrst (LMNA1, Fig. 1B) presenting normal
serum levels of TGF b2, the second (LMNA3, Fig. 1B),
presenting both TGF b2 and IL6 increase in serum. A
third subgroup of patients (LMNA2, Fig. 1B), which
represented 82% of all examined cases, showed
increased levels of TGF b2 and IL17, while IL6 level
was slightly decreased. Moreover, in all EDMD sera,
neither TGF b1 nor TGF b3 were signiﬁcantly affected
(Fig. 1C). All patients included in LMNA 1–3 sub-
groups were symptomatic, presenting muscle weak-
ness and wasting and/or cardiomyopathy with
conduction disorders (Table 1). Asymptomatic indi-
viduals bearing EDMD2-linked LMNA mutations did
not show increase of TGF b2 levels and presented nor-
mal levels of IL6, while IL17 secretion was moderately
increased (Fig. 1S). In muscle biopsies from EDMD2
patients, TGF b2 mean ﬂuorescence intensity was
increased in the perimisium (Fig. 1D). Since LMNA
mutations in the examined patients had been deter-
mined all along the protein sequence (Fig. 1E), ruling
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out the possibility of site-speciﬁc effects, these data
suggested that either altered cytokine secretion was
triggered by the ongoing degenerative process affect-
ing skeletal or cardiac muscle or it was part of the cel-
lular response to mutated LMNA expression. The
following paragraphs report experiments aimed at
evaluating both hypotheses for TGF b2.
TGF b2 levels are increased in LmnaH222P/H222Pmice
Elevated TGF b2 secretion has been linked to activation
of AKT/mTOR signaling and neutralization of TGF b2
has been shown to restore altered AKT/mTOR
signaling in cells bearing LMNAmutations [11]. Activa-
tion of the same signaling pathway has been also
reported in LmnaH222P/H222Pmice that also showed tran-
scriptional activation of TGF b2 [13, 14]. Here, we eval-
uated serum levels of TGF b2 in LmnaH222P/H222Pmice13
and Lmna null mouse cells [17] (Fig. 2A). TGF b2 was
elevated in serum from LmnaH222P/H222P mice (Fig. 2A),
consistent with the reported mRNA increase previously
shown in this mouse model [13]. Using Lmna null
mouse cultured ﬁbroblasts we obtained an unexpected
result. In fact, compared to Lmna +/+ cell culture
medium, TGF b2 levels were signiﬁcantly increased in
Lmna +/- and decreased in Lmna ¡/¡ cell culture
Figure 1. Cytokine level is affected in muscular laminopathies. (A) Levels of TGF b2 in sera of healthy donors (control), patients affected
by muscular laminopathies (LMNA) and patients affected by other neuromuscular diseases, including Duchenne Muscular dystrophy,
Becker muscular dystrophy and Myotonic Dystrophy (others). (B) Levels of TGF b2, IL6, IL17 and FGF-b in sera of controls and LMNA
symptomatic patients. Based on cytokine expression pattern, sera from LMNA symptomatic patients are divided in three subgroups
(LMNA1, LMNA2, LMNA3); the percentage of patients in each subgroup out of all examined LMNA patients is reported. (C) Levels of TGF
b1, TGF b2, TGF b3 in sera of controls and LMNA patients. (D) Representative image of immunoﬂuorescence detection of TGF b2 (green)
in control and LMNA muscle tissue (in this case R190Q/R249Q heterozygous compound mutation in LMNA was determined in the
EDMD2 patient). Nuclei are stained with DAPI. Bar: 10mm. (E) Scheme of LMNA mutations detected in laminopathic patients examined
in this study. Means § standard deviation are shown in graphs. Statistically signiﬁcant differences are indicated by an asterisk (p<0.05),
double asterisk (p<0.01) or triple asterisk (p< 0.001).
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medium (Fig. 2B). These results could indicate that the
presence of non-functional lamin A/C is necessary to
trigger TGF b2 secretion, as previously reported in
other laminopathic models [11].
TGF b2 induces a ﬁbrogenic process in myoblasts
Elevated TGF b2 levels were not only detected in
EDMD2 serum, but also in EDMD2 ﬁbroblast culture
media (Fig. 3A). Thus, we hypothesised a double effect
of lamin A/C mutations on muscle functionality,
caused by local and systemic TGF b2 increase. To con-
ﬁrm the parabiotic effect of TGF b2 on human muscle
cells, we co-cultured normal human myoblasts (NHM)
with EDMD2 ﬁbroblasts. Cell culture conditioning
increased the number of myoﬁbroblasts,
as determined by counting alpha-smooth muscle
actin (alpha-SMA) and ED-ﬁbronectin [18] positive
(double-labelled) cells (Fig. 3B). These results indicated
activation of a ﬁbrogenic process. Moreover,
Table 1. List of patients involved in the study.
Pathology LMNA mutation Gender Age Symptoms Heart surgery
EDMD 2 c.1007G>A M 58 Dilated cardiomyopathy, conduction defects, atrial ﬁbrillation ICD
EDMD 2 c.1007G>A M 27 Dilated cardiomyopathy, conduction defects, atrial ﬁbrillation ICD
EDMD 2 c.1007G>A M 43 Dilated cardiomyopathy, conduction defects, atrial ﬁbrillation ICD
EDMD 2 c.471C>A M 35 Dilated cardiomyopathy, conduction defects, atrial ﬁbrillation ICD
EDMD 2 c.625delA M 30 Dilated cardiomyopathy, conduction defects, atrial ﬁbrillation
EDMD 2 c.937-11 c>g (IVS5-11C>G) F 49 Dilated cardiomyopathy, conduction defects, atrial ﬁbrillation ICD
EDMD 2 c.937-11 c>g (IVS5-11C>G) F 20 Cardiomyopathy and conduction defects, atrial ﬁbrillation
EDMD 2 c.625delA M 45 Cardiomyopathy and conduction defects
EDMD 2 c.812T>C M 30 Cardiomyopathy and conduction defects, atrial ﬁbrillation
EDMD 2 c.799T>C F 22 Rigid spine, muscular dystrophy, early signs of cardiac compromise,
cardiomyopathy
EDMD 2 c.799T>C M 20 Atrial ﬁbrillation, cardiac conduction disease, biatral enlargement
EDMD2 c.854T>A M 38 Diffuse muscle weakness, early contractures, atrial ﬁbrillation
CMD1A c.1608+1G>T M 38 Ventricular extrasystoles, dilated cardiomyopathy (slight left
ventricular dilation)
LGMD1B c.1608+1G>T M 50 Mild axial and pelvic girdle muscle weakness, bundle branch block,
atrial ﬁbrillation, mild left ventricular dilatation
ICD
CMD1A c.1102_1130dup M 34 Ventricular tachyarrhythmia, slight left ventricular dilation with
preserved systolic function
ICD
LGMD1B c.1102_1130dup F 63 Muscle weakness and wasting, contractures, cardiomyopathy heart transplantation
CMD1A c.1608+1G>T F 40 Ventricular extrasystoles, tachyarrhythmias ICD
LGMD1B c.IVS5-11C>G (c.937-11C>G) F 37 Cardiomyopathy and conduction defects, atrial ﬁbrillation
LGMD1B c.937-11 c>g (IVS5-11C>G) M 45 Cardiomyopathy and conduction defects, atrial ﬁbrillation
LGMD1B c.937-11 c>g (IVS5-11C>G) F 41 Cardiomyopathy and conduction defects, atrial ﬁbrillation
LGMD1B c.937-11 c>g (IVS5-11C>G) F 77 Cardiomyopathy and conduction defects, atrial ﬁbrillation
EDMD 2 c.799T>C F 45 Cardiomyopathy and conduction defects
EDMD 2 c.812T>C M 45 Cardiomyopathy and conduction defects
EDMD2 UN M 34 Muscle weakness and wasting
EDMD2 UN M 21 Muscle weakness and wasting
EDMD2 UN M 23 Muscle weakness and wasting
EDMD2 UN M 25 Asymptomatic
EDMD2 c.1357C>T F 54 Muscle weakness and contractures, dilated cardiomyopathy,
conduction disease
EDMD2 c.1357C>T F 21 Muscle weakness and contractures, dilated cardiomyopathy,
conduction disease
LGMD1B c.1718C>T F 67 Muscle weakness and wasting
EDMD2 c.1960C>T F 43 Axonal Neuropathy
EDMD2 c.214C>T F 23 Muscle weakness and wasting
EDMD2 c.1718C>T M 64 Iper-CK, myalgia
EDMD2 c.1718C>T F 54 Muscle weakness and wasting
EDMD2 c.1718C>T M 45 Muscle weakness and wasting
LGMD1B c. 1146C>T+c.1698C>T F 34 Muscle weakness and wasting
LGMD1B c.1130G>A M 35 Muscle weakness and wasting
EDMD2 c.1130G>A F 81 Asymptomatic
LGMD1B c.1130G>A M 30 Muscle weakness and wasting
EDMD2 UN M 39 Muscle weakness, cardiomyopathy, conduction disease
EDMD2 UN M 39 Muscle weakness, cardiomyopathy, conduction disease
CMD1A c 357-IG>A (IVSI-IG>A) M 24 Muscle weakness, dilated cardiomyopathy
CMD1A c 357-IG>A (IVSI-IG>A) F 51 Muscle weakness, dilated cardiomyopathy
EDMD2 c.775T>G M 27 Muscle weakness and wasting, contractures, cardiomyopathy ICD
LGMD1B c.80C>T M 59 Muscle weakness and wasting, cardiomyopathy ICD
LGMD1B c.80C>T M 33 Muscle weakness, dilated cardiomyopathy ICD
LGMD1B c.80C>T F 52 Muscle weakness and wasting, cardiomyopathy ICD
EDMD2 c.80C>T M 26 Asymptomatic
LGMD1B c.80C>T F 57 Muscle weakness and wasting, cardiomyopathy,
EDMD2 c.80C>T M 28 Asymptomatic
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intracellular collagen I was increased in conditioned
myoblasts [9] (Fig. 3C), demonstrating that a ﬁbrogenic
process could be stimulated by EDMD2 ﬁbroblasts in
NHM. Differentiating myoblasts conditioned by con-
trol cells did not show collagen I staining [9] (Fig. 3C).
Conversely, EDMD2 medium induced upregulation of
collagen I in cycling myoblasts and even in myogenin-
positive committed myoblasts, but not in myotubes
(Fig. 3C). To establish the involvement of TGF b2 in
that mechanism, we inhibited growth factor activity by
a speciﬁc neutralizing antibody [19]. Neutralization of
TGF b2 reduced collagen I production to levels compa-
rable to controls (Fig. 3C) indicating that the ﬁbrogenic
process was mostly driven by TGF b2 signaling. In
agreement with those ﬁndings, we observed that the
ﬁbrogenic marker ED-ﬁbronectin (Fig. 3D) was
increased in muscle ﬁbers from EDMD2 patients,
though did not reach the high levels observed in BMD
muscle (Fig. 3E). These results showed that collagen I-
positive myogenic cells were formed in the presence of
TGF b2 and contributed to dysregulation of the
extracellular matrix in muscle tissue. To test the effect
of TGF b2 on cellular proliferation, we analyzed the
cell cycle in the presence or not of conditioning media.
Myoblast proliferation was stimulated by EDMD2
medium, while neutralization of TGF b2 slightly
reduced the proliferation rate (Fig. 3E). This result sug-
gested that the EDMD2 secretome stimulated myoblast
proliferation at in least in part through TGF b2.
TGF b2 impairs myoblast differentiation
Increased proliferation of muscle precursors could
affect myogenic differentiation rate, contributing to
muscular dystrophy [20]. To test the hypothesis that
TGF b2 could contribute to altered myoblast differenti-
ation in EDMD2, we explored the effect of the EDMD2
secretome on myotube formation. Mouse C2C12 myo-
blast differentiation was impaired to a signiﬁcant extent
by EDMD2 ﬁbroblast culture medium and could be
rescued by neutralization of TGF b2 activity as demon-
strated by counting cells positive for myogenic markers
[6] including myogenin and caveolin 3 (Fig. 4A, B).
Also in NHM treated with EDMD2 medium, differenti-
ation rate was signiﬁcantly reduced in a TGF b2-depen-
dent way (Fig. 4C). These data demonstrated that TGF
b2 levels affect the turnover of muscle cells and the
myogenic process can be re-activated by its blockade.
TGF b2 affects tenocyte differentiation favoring
ﬁbrosis
Tenocytes represent possible effectors of EDMD2 patho-
genesis, since contractures of the Achilles tendons and
elbows are the ﬁrst sign of disease in most affected indi-
viduals [1]. Here, we tested the hypothesis that elevated
TGF b2 levels might interfere with tenocyte differentia-
tion and induce a ﬁbrotic phenotype. TGF b2 is an
inducer of collagen I in tenocytes and the process con-
tributes to differentiation [21,22]. However, an amount
of TGF b2 comparable to that observed in patient serum
caused a striking increase of alpha-SMA, a marker of
myoﬁbroblasts, in control tenocytes (Fig. 5A). Moreover,
in control tenocytes cultured in the presence of EDMD2
serum, conversion to myoﬁbroblasts, labeled by alpha-
SMA was observed and alpha-SMA overall ﬂuorescence
intensity was signiﬁcantly increased (Fig. 5A). Impor-
tantly, neutralization of TGF b2 reduced the rate of
ﬁbrogenic conversion, as shown by reduced alpha-SMA
positivity (Fig. 5A).
Figure 2. TGF b2 level is increased in laminopathic mice. (a) Levels
of TGF b2 in sera of WT mice (n = 6) and LmnaH222P/H222P mice
(LmnaH222P) (n = 5). (b) Levels of TGF b2 secreted by ﬁbroblasts
isolated from WT mice (Lmna +/+), mice bearing heterozigous
(Lmna +/¡) or homozygous (Lmna ¡/¡) null mutation in Lmna
gene and maintained in culture for 5 days. Means§ standard devi-
ation are shown in graphs. Statistically signiﬁcant differences are
indicated by an asterisk (p<0.05) or double asterisk (p< 0.01).
NUCLEUS 341
As expected [22], TGF b2-treated tenocytes expressed
high tenomodulin levels (Fig. 5B). The same effect was
elicited by culturing tenocytes in EDMD2 serum
(Fig. 5B). Thus, EDMD2 serum triggered the expres-
sion of a late tenocyte differentiation marker by mim-
icking the effect of TGF b2.
The whole evaluation of the above reported data led
us to the conclusion that excess levels of TGF b2 drive
ﬁbrotic processes in EDMD2 tendons and muscle
cells, while also enhancing tenocyte differentiation.
TGF b2 signaling in EDMD2
To test the signalling pathway downstream of TGF b2,
we examined control and EDMD2 myoblast lysates by
western blot analysis. Statistically signiﬁcant increase of
mTOR phosphorylation was determined in EDMD2
myoblasts (Fig. 6A). However, in ﬁbroblasts from
EDMD2 subjects, mTOR phosphorylation was not
affected, whereas Akt was activated, as demonstrated by
increase of serine 308 and serine 473 phosphorylation
(Fig. 6B). Importantly, neutralization of TGF b2,
Figure 3. EDMD2 ﬁbroblast medium induces TGF b2-dependent ﬁbrogenic conversion in NHM cultures. (A) TGF b2 secretion in control and
EDMD2 ﬁbroblast culture medium. (B) Quantiﬁcation of myoﬁbroblasts in cultures of control human myoblasts maintained in medium con-
ditioned by control (control) or EDMD2 (EDMD2) ﬁbroblasts or treated with TGF b2 (control + TGF b2). The number of myoﬁbroblasts was
determined by counting alpha-SMA positive mononucleated cells (200 cells/sample were counted in three independent experiments). (C)
Immunoﬂuorescence staining of collagen I (green) and desmin (red) in cycling and differentiated NHM cultured in presence of medium
conditioned by control or EDMD2 ﬁbroblasts, treated (anti-TGFb2) or not (NT) with anti-TGF b2 neutralizing antibodies. Nuclei were stained
with DAPI. Bar: 10mm. (D) Immunoﬂuorescence staining of ED-ﬁbronectin (red) in cryosections of muscle tissue isolated from healthy
donors (control), EDMD2 patients (EDMD2) or Becker muscular dystrophy patients (BMD). Nuclei were stained with DAPI. BMD tissue was
used as positive control. In control muscle, ED-ﬁbronectin is restricted to the area surrounding blood vessels. Bar: 10mm. (E) Quantitative
analysis of proliferating cells in NHM cultures maintained in medium conditioned by control or EDMD2 ﬁbroblasts, treated (anti-TGF b2) or
not (NT) with anti-TGF b2 neutralizing antibodies. The number of proliferating cells was determined by ﬂow cytometry. Means§ standard
deviation are shown in graphs. Statistically signiﬁcant differences are indicated by double asterisk (p<0.01) or triple asterisk (p< 0.001).
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obtained by adding the speciﬁc antibody in cell cultures,
reduced mTOR phosphorylation in myoblasts and AKT
phosphorylation in ﬁbroblasts (Fig. 6). These results
showed that increased TGF b2 secretion elicits AKT/
mTOR activation in EDMD2 cells through diverse
branches of the signalling pathway in diverse cell types.
Discussion
The reported study provides several advances in the
understanding of EDMD2 pathogenesis. 1) Increase of
TGFbeta 2 secretion is identiﬁed as a hallmark of dis-
ease both in patient serum and in animal models as
well as in cell cultures derived from patient muscle
biopsies. 2) Activation of AKT/mTOR pathway is
demonstrated as an effect of increased TGFbeta 2 sig-
naling in EDMD2 myoblasts. 3) Fibrogenic response
to TGF beta 2 secretion is determined both in human
myoblasts and tenocytes. 4) Tenocytes are recognised
as a relevant target of disease in EDMD2, based on
their response to EDMD2 secretome stimulus. 5) Neu-
tralizing TGF beta 2 antibodies are indicated as a
potential therapeutic tool to be further explored in
preclinical models.
The consistent increase in TGFbeta 2 secretion
determined in EDMD2 patients, irrespective of
mutated LMNA sequence, gender and age of patients,
allows us to propose TGFbeta 2 as the ﬁrst circulating
biomarker of this disease. Of note, TGFbeta 2 levels in
EDMD2 were compared to those measured in DMD
serum [8] and found to be signiﬁcantly higher. This
ﬁnding hints to a speciﬁc effect of LMNA mutations
on TGFbeta 2 regulation that is not fully elucidated.
Our previous data obtained in primary cells and
Figure 4. EDMD2 ﬁbroblast medium inhibits differentiation of NHM through TGF b2. (A) Immunoﬂuorescence staining of myogenin
(red) and caveolin 3 (green) in C2C12 myoblasts cultured in presence of control or EDMD2 ﬁbroblast medium. Data from samples left
untreated (NT) or treated with anti-TGF b2 antibody (anti-TGF b2) are reported. Nuclei are counterstained with DAPI. Bar: 10mm. (B) Per-
centage of differentiated cells in C2C12 myoblast cultures conditioned by control or EDMD2 medium. Data from samples left untreated
(NT) or treated with anti-TGF b2 antibody (anti-TGF b2) are reported. (C) Percentage of differentiated NHM conditioned by EDMD2
medium. Data from samples left untreated (NT) or treated with anti-TGF b2 antibody (anti-TGF b2) are reported. Means § standard
deviation are shown in graphs. Statistically signiﬁcant differences are indicated by an asterisk (p<0.05) or double asterisk (p< 0.01).
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experimental models of progeroid laminopathies,
show that mutated lamin A/C fails to downregulate
this cytokine, while wild-type lamin A does repress
TGF beta 2 expression [11]. We further showed that
secreted TGFbeta 2 is able to activate Akt phosphory-
lation in osteoblast-like cells and ﬁbroblasts [11] lead-
ing to degradation of lamin A itself [11,23–25]. Thus,
we suggest that lamin A-TGFbeta 2 interplay could
contribute to reduce LMNA expression in the presence
of mutated lamin A. This hypothesis and the possibil-
ity that lamin A might in turn inﬂuence TGF beta 2
expression at the transcriptional level warrant further
investigation.
In this study, we show that the mTOR pathway is
activated in EDMD2 myoblasts and the mechanism is
dependent on TGFbeta 2, as demonstrated by the
inhibitory effect exerted by neutralizing TGFbeta 2
antibodies. Of note, we found a different response to
TGF beta 2 secretion in ﬁbroblasts versus myoblasts
even from the same affected individual. Akt serine 473
and 308 phosphorylation was in fact increased in
ﬁbroblasts in a TGF beta -2 dependent fashion, but
not in myoblasts, while mTOR phosphorylation was
selectively increased in myoblasts. This results could
suggest that mTOR activation in myoblasts triggers
mTORC1-dependent Rictor phosphorylation that
inhibits mTORC2-mediated Akt phosphorylation
[26]. Conversely, direct activation of Akt, possibly
dependent on Erk 1/2 phosphorylation [13], likely
occurs in EDMD2 ﬁbrobalsts, as determined in other
laminopathic ﬁbroblasts [11] and in mouse models
[13].
A plethora of effects may potentially derive from
Akt/mTOR activation. Increased mTOR phosphoryla-
tion, here determined in EDMD2 myoblasts, is
expected to impair the autophagic process, as previ-
ously reported in animal models of EDMD2 by Ramos
et al [15]. and Choi et al [14]. Here, we did not investi-
gate changes in autophagic processes, an issue that will
be addressed in further studies. Rather, we focused on
the effect elicited by TGF beta 2 on the ﬁbrogenic pro-
cess. Upstream of ﬁbrogenic mechanisms, both
mTOR activation and mTOR-independent Akt phos-
phorylation may occur [13,27]. In fact, simultaneous
activation of the mTOR subunits mTORC1 and
mTORC2 has been shown to mediate TGF beta 2-
dependent upregulation of a-SMA and myoﬁbroblast
formation [27]. On the other hand, collagen I and
connective tissue growth factor (CTGF) upregulation
related to Akt hyperactivation has been demonstrated
in laminopathic LmnaH222P/H222P mice [13,28]. Thus,
it is tempting to speculate that different branches of
TGFbeta 2 signaling pathway contribute in a cell/tis-
sue-speciﬁc way to the onset of ﬁbrosis in EDMD2. A
Figure 5. TGF b2 from EDMD2 serum induces ﬁbrosis markers in normal human tenocytes. (A) Immunoﬂuorescence staining of alpha-
SMA in normal human tenocytes cultured in the presence of control serum, control serum + TGF b2, EDMD2 serum or EDMD2 serum +
anti-TGF b2. Nuclei were counterstained with DAPI. Bar, 20 mm. Quantitative analysis of mean ﬂuorescence intensity of alpha-SMA is
reported in the graph. (B) Western blot analysis of ED-ﬁbronectin, tenomodulin and alpha-SMA in control tenocytes exposed to control
serum, control serum + TGF b2 or EDMD2 serum. Densitometric analysis of immunoblotted bands is reported in the graphs. Means §
standard deviation are shown in graphs. Statistically signiﬁcant differences are indicated by an asterisk (p<0.05), double asterisk (p<
0.01) or triple asterisk (p< 0.001).
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demonstration of engagement of mTOR in a tissue-
speciﬁc way has been reported in response to insulin
stimulus [29] and different levels of proteins of the
Akt/mTOR pathway have been found in human tis-
sues [30].
Fibrosis was previously determined in mouse mod-
els of EDMD2, especially in myocardium [13]. More-
over, several reports documented ﬁbrotic areas in
muscle and heart of EDMD2 patients [31-33]. Here,
we provide a mechanistic explanation of this phenom-
enon by showing involvement of TGFbeta 2. More-
over, we identify for the ﬁrst time a major role of
TGFbeta 2 in the activation of ﬁbrotic process in
tenocytes. Although tenocytes from EDMD2 individu-
als were not available, our data show that EDMD2 cell
culture medium or serum from laminopathic patients
strongly increase both levels of proﬁbrotic factors
alpha-SMA and collagen I and expression of the late
tenocyte marker tenomodulin [22]. The major role of
TGFbeta 2 on tendon progenitor cell recruitment, col-
lagen I and tenomodulin upregulation and tenocyte
differentiation is well documented [22,34]. The condi-
tion we envisage in EDMD2 may affect tendon func-
tionality by inducing both dysregulated differentiation
and formation of myoﬁbroblasts, typical of ﬁbrotic tis-
sue. An interesting clinical observation in EDMD2 is
Figure 6. TGF b2 affects the AKT/mTOR pathway in EDMD2. Western blot analysis of p-mTOR, mTOR, Thr308 Akt, Ser473 Akt, Akt and
actin performed in (A) control myoblasts (control), EDMD2 myoblasts (EDMD2) and EDMD2 myoblasts treated with anti-TGF b2 neutral-
izing antibody (EDMD2 + anti-TGF b2) or (B) control ﬁbroblasts (control), EDMD2 ﬁbroblasts (EDMD2) and EDMD2 ﬁbroblasts treated
with anti-TGF b2 neutralizing antibody (EDMD2 + anti-TGF b2). Actin bands are shown as protein loading control. Molecular weight
markers are reported in kDa. Densitometric analysis of immunoblotted bands normalized on actin is reported in the graphs. Means §
standard deviation are shown in graphs. Statistically signiﬁcant differences are indicated by an asterisk (p<0.05), double asterisk (p<
0.01) or triple asterisk (p< 0.001).
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that contractures are in most cases a ﬁrst symptom of
disease, often preceding muscle weakness and wasting
[1]. Our ﬁnding that TGFbeta 2 increase is a common
trait of symptomatic patients affected by muscular
laminopathies, even at early stages of disease progres-
sion, may in part explain the early occurrence of ten-
don contractures. In this respect, it is worth
mentioning data obtained in a mouse model that dem-
onstrate different response of tenocytes to TGFbeta 2
stimulus, depending on development stage and/or
mechanical loading [22]. Thus, it is possible that ele-
vated TGFbeta 2 secretion elicits tenocyte defects and
contributes to contractures in a deﬁned period of ten-
don development. This is consistent with the observa-
tion that many EDMD2 patients undergo Achilles
tendon lengthening to resolve contractures and toe
walking at a very young age and do not experience
any further problems in the following years. This issue
warrants investigation in view of potential pharmaco-
logical treatments.
Both in muscle cells and tenocytes, we show that a
neutralizing TGFbeta 2 antibody may reduce ﬁbro-
genic markers. To which extent this antibody could be
exploited to counteract in vivo ﬁbrosis and altered cel-
lular differentiation must be assessed in preclinical
studies. So far, we cannot rule out the possibility that
high TGFbeta 2 levels in laminopathic patients might
be protective through the mTOR-dependent pathway
leading to degradation of mutated lamin A11.
In support of this possibility, we recently observed
that patients affected by the most severe form of mus-
cular laminopathy, the LMNA-related congenital mus-
cular dystrophy (L-CMD), show an overall altered
cytokine proﬁle, but normal levels of TGFbeta 2.
Overall, in the study here reported, TGFbeta 2
emerges as a biomarker of disease for EDMD2 and
LGMD1B to be further explored as therapeutic target.
Materials and methods
Patients
Fifty EDMD2 and LGMD1B patients were involved in
this study. Information on LMNA mutation, pheno-
type, sex and age of patients at collection of biological
samples is reported in Table 1. All patients gave their
written informed consent and the study was approved
by the ethical Committee of the Fondazione Neuro-
logica Carlo Besta in Milan that coordinated secre-
tome analysis.
Serum samples
Serum samples were collected from previously charac-
terized EDMD2 and LGMD1B patients (Table 1).
Serum from 22 healthy donors (3 males and 19
females, age range: from 23 to 50 years) was also
tested. Frozen serum samples were gathered and sub-
jected to multiple cytokine screening at the Fonda-
zione Neurologica Carlo Besta Institute.
Animal samples
Serum samples were collected from LmnaH222P/H222P
mice fed chow and housed in a disease-free barrier
facility with 12 h/12 h light/dark cycles. Blood collec-
tion was performed according to Ministere de
l 0Education Nationale de l’Enseignement Superieur et
de la Recherche France at Center for Research in
Myology Paris.
Cell culture and treatments
Human myoblast and ﬁbroblast cultures were
obtained from healthy donors, LGMD1B patients car-
rying the Y259D LMNA mutation [6] or EDMD2
patients bearing the H506P LMNA mutation [35].
Tenocytes were established from biopsies of healthy
donors undergoing orthopaedic surgery. Muscular tis-
sue was from biopsies of healthy donors, patients
affected by EDMD2 (LMNA H506P mutation) or
Becker muscular dystrophy (BMD). These samples
belong to the BioLaM biobank hosted at Rizzoli
Orthopaedic Institute-CNR Institute of Molecular
Genetics in Bologna. All samples were obtained fol-
lowing written consent and according to Italian and
EU rules. Fibroblast cultures from adult Lmna+/+,
Lmna+/¡ and Lmna¡/¡ mice were established and
characterized at the CNR Institute of Cellular Biology
and Neurobiology, according to approved experimen-
tal protocols. Mouse C2C12 cells from the European
Cell Culture Collection were purchased from Sigma.
Human myoblasts and ﬁbroblasts were grown in
Dulbecco’s modiﬁed Eagle’s medium – High Glucose
(DMEM-HG), supplemented with 20% fetal bovine
serum (FBS) and antibiotics mix, at 37C, 5% CO2.
C2C12 myoblasts were grown in DMEM supple-
mented with 10% FBS, at 37C and 5% CO2. Human
control myoblasts plated in 12-well tissue culture
plates were cultured in the presence of conditioned
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medium from healthy donor (control) or EDMD2
ﬁbroblasts.
In order to neutralize TGF b2, human myoblast
and C2C12 cultures were treated for 72 hours with
human TGF b2 neutralizing antibody (ab66045,
Abcam, Cambridge, UK) at the concentration of
0,03 mg/ml or mouse TGF b2 neutralizing antibody at
the concentration of 0,01 mg/ml (MAB7346, R&D
System, Abington, UK), respectively.
Control tenocytes were cultured in the presence of
serum from healthy donors (control) or EDMD2
patients. Moreover, TGF b2 was added to some teno-
cyte cultures at the concentration of 1 ng/mL for
72 hours [34].
Western blot analysis
Whole cell lysates were prepared in RIPA buffer
(20 mM Tris-HCl, pH 7.0, 1% Nonidet P-40, 150 mM
NaCl, 10% glycerol, 10 mM EDTA, 20 mM sodium
ﬂuoride, 5 mM sodium pyrophosphate, 1 mM
Na3VO4, 1 mM PMSF, 10 mg/ml leupeptin and
10 mg/ml pepstatin) by incubation at 4C for
30 minutes. Protein concentration of samples was
determined using the Bradford protein assay (Bio-Rad
Laboratories, Mitry-mory, France). 50 mg of protein
lysate were diluted in sample buffer, subjected to SDS-
PAGE and transferred to nitrocellulose membrane
(BioRad). Membranes were saturated with 4% BSA
and incubated with primary antibodies overnight at
4C. Secondary antibodies were incubated for 1 hour
at room temperature. Immunoblotted bands were
revealed by enhanced chemiluminescence (Amersham
ECL detection system, GE Healthcare). Intensity mea-
surement was performed using a BioRad densitometer
(GS 800) equipped with Quantity One Software. Actin
was used as a protein loading control for quantitative
analysis.
Immunoﬂuorescence
Myoblasts grown on coverslips were ﬁxed with 4%
parafolmaldehyde at 4C and permeabilized with
0.15% TRITON X-100 at room temperature. Non-spe-
ciﬁc binding was avoided by saturating samples with
4% BSA in PBS. Coverslips were then incubated over-
night at 4C with primary antibody and 1hour at
room temperature with secondary antibody and coun-
terstained with DAPI. Samples were analyzed with a
Nikon Eclipse Ni ﬂuorescence microscope using the
NIS AR software. All images were taken at similar
exposures within an experiment for each antibody.
Images were processed using Adobe Photoshop 7
(Adobe Systems).
Antibodies
Primary antibodies for immunoblotting and/or immu-
noﬂuorescence were goat polyclonal alpha-SMA
(ab5694, Abcam, Cambridge, UK), mouse monoclonal
anti-ﬁbronectin (ab6328, Abcam, Cambridge,UK),
rabbit polyclonal anti- myogenin (sc576, Santa Cruz
Biotechnology, Heidelberg, Germany), rat monoclonal
anti-caveolin 3 (BD 610421, BD Transduction Labora-
tories, USA), rabbit polyclonal anti-TGF b2 (sc90,
Santa Cruz Biotechnology, Heidelberg, Germany),
rabbit polyclonal anti-collagen I antibody (ab34710,
Abcam, Cambridge, UK), anti-desmin (MA1-22150,
Sigma), anti-tenomodulin (ab81328, Abcam, Cam-
bridge, UK), anti-actin (Santa Cruz).
Cytometry
The percentage of cells in the G0/G1, S and G2/M
phase of the cell cycle was determined by the Muse
Cell Analyzer (Merck Millipore, France) using Muse
Cell Cycle Kit following manufacturer’s instructions.
Quantiﬁcation of cytokine levels in sera
and culture media
Sera derived from EDMD2 patients and from healthy
donors were analyzed using Bio-Plex Pro Human 27-
plex Assay kit (Bio-Rad Laboratories) and TGF b 3-
plex kit (Bio-Rad Laboratories, Mitry-mory, France)
following manufacturer’s instructions. TGF b2 secre-
tion in culture media was measured by ELISA accord-
ing to the protocol supplied by the manufacturer (Bio-
Rad Laboratories, Mitry-mory, France).
Statistical analysis
Statistical analysis was performed using Graphpad
software (Prism, California, USA). Student’s t test was
used for comparisons between two groups and one-
way ANOVA with Tukey’s post hoc test was used for
comparisons between multiple groups. Signiﬁcance
was accepted at p < 0.05 and data are presented as
mean § standard deviation of the mean.
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